Inmagene Biopharmaceuticals picks up $21m Series B

Inmagene Biopharmaceuticals, a Chinese drug developer, has secured $21 million in Series B financing.

9 November 2020•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles